LANSING, Mich. — Sparrow has become the first hospital in the nation to successfully implant an aortic valve replacement aimed at reducing leakage around the heart and lead to better patient outcomes.
The Navitor transcatheter aortic valve, developed by Abbott, is inserted through a catheter via an artery in the top of the leg to replace the old valve. The process means a quicker recovery for patients. The Structural Heart Team at Sparrow – Gaurav Dhar, M.D., Nam Cho, M.D., and Hisham Qandeel, M.D. – recently performed the procedure on a high-risk patient who recovered well and was discharged the following day.
Sparrow is the only site in Michigan that’s part of a nationwide clinical trial in which the valve is being studied.
“Participating in the clinical trial to evaluate the Navitor valve has allowed Sparrow to make cutting-edge technology available to the people of Michigan,” said Dr. Dhar, an interventional cardiologist. “We are honored to be the first to enroll in this important trial.”
TAVR is a minimally invasive alternative to surgical aortic valve replacement for patients who are diagnosed with severe aortic stenosis – a common and serious valve disease that restricts blood flow through the valve. More than one in eight people aged 75 and older have moderate or severe aortic stenosis, which is caused by a narrowing of the aortic valve opening in the heart that restricts blood flow from the left ventricle to the aorta.
Check out other Health related articles in our Yes to Healthy Living section of our website.
Stay in touch with us anytime, anywhere.
Sign up for newsletters emailed to your inbox.
Select from these options: Breaking News, Severe Weather, School Closings, Daily Headlines and Daily Forecasts.